Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385228 · ClinicalTrials.gov registry record · Phase 1
Pazopanib, Docetaxel, Prednisone Prostate
A Phase 1 study, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01385228 is a Phase 1 study that has completed, run by Daniel George, MD. The registered enrollment target is 36 participants.
The verdict
NCT01385228, a Phase 1 study, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Pazopanib
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385228
The ClinicalTrials.gov registry entry for NCT01385228 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel George, MD, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01385228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01385228 about?
NCT01385228 is a clinical study titled "Pazopanib, Docetaxel, Prednisone Prostate". The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).
What is the current status of trial NCT01385228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-06. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01385228?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Pazopanib (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT01385228?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.